Quantcast

Latest Antiplatelet drug Stories

2014-06-12 08:28:30

ZWOLLE, The Netherlands, June 12, 2014 /PRNewswire/ -- Randomized Evaluation of short-term DUal antiplatelet therapy in patients with acute coronary syndrome treated with the COMBOTM Dual-Therapy StEnt The Principal Investigators of the REDUCE trial announce the enrolment of the first patient in the REDUCE trial with the OrbusNeich COMBO Dual Therapy Stent at Isala Hospital, Zwolle, the Netherlands. According to the local PI and treating physician, Doctor E....

2014-03-18 23:33:25

Rapid CYP2C19 Testing for Personalized Antiplatelet Therapy in 600-Patient Clinical Trial with Spartan Bioscience (PRWEB) March 18, 2014 Spartan Bioscience today announced the start of a 600-patient study of personalized medicine for cardiac stent patients in Germany. The study is part of a larger clinical trial entitled “Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes Trial (TROPICAL-ACS)”. TROPICAL-ACS, led by principal...

2014-02-04 20:22:49

DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/vgwhc9/new_oral) has announced the addition of the "Concise Analysis of the International New Oral Anticoagulants Markets" [http://www.researchandmarkets.com/research/vgwhc9/new_oral ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Anticoagulants decrease the ability of the blood to create harmful blood clots that can...

2013-10-14 23:20:48

Reportbuyer.com just published a new market research report: Cardiovascular Disease: Recent Drug Advances and Impending Risks. London (PRWEB) October 14, 2013 There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace. Successful...

2013-09-01 23:01:39

Icahn School of Medicine at Mount Sinai Presents New Findings of their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) Study at European Society of Cardiology 2013 Congress New York, NY (PRWEB) September 01, 2013 Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC Congress 2013 in Amsterdam organized by the European...

2013-08-19 10:14:30

Older heart patients present unique challenges for determining the optimal dosages of medications, so a new study from researchers at Duke Medicine offers some rare clarity about the use of drugs that are used to treat patients with heart attacks. For certain heart patients older than age 75, a half-dose of the anti-platelet drug prasugrel works about as well as the typical dosage of clopidogrel, according to a team led by the Duke Clinical Research Institute that looked at a sub-study of...

2013-07-26 18:38:55

Study finds that high platelet reactivity on clopidogrel predicts stent thrombosis, heart attack, and bleeding but is not directly linked to death Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less likely to develop bleeding complications. One-year results of the ADAPT-DES trial will be published online July 26, 2013, in...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related